MOLECULAR ASSESSMENT OF KIDNEY ALLOGRAFTS: ARE WE CLOSER TO A DAILY ROUTINE?

Andriy Trailin[1], Petra Hruba[1] and Ondrej Viklicky[1,2]

[1]*Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, [2]Department of Nephrology, Transplant Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic*

Correspondence:

Ondrej Viklicky, MD, PhD

Professor of Medicine

Department of Nephrology, Transplant Centre

Institute for Clinical and Experimental Medicine

Videnska 1958/9, 14021 Prague, Czech Republic

onvi@ikem.cz

Short title: Molecular assessment of kidney allografts

Conflict of Interest

The authors declare no conflicts of interest.

Summary

Kidney allograft pathology assessment has been traditionally based on clinical and histological criteria. Despite improvements in Banff histological classification, the diagnostics in particular cases is problematic reflecting a complex pathogenesis of graft injuries. With the advent of molecular techniques, polymerase-chain reaction, oligo- and microarray technologies allowed to study molecular phenotypes of graft injuries, especially acute and chronic rejections. Moreover, development of the molecular microscope diagnostic system (MMDx) to assess kidney graft biopsies, represents the first clinical application of a microarray-based method in transplantation. Whether MMDx may replace conventional pathology is the subject of ongoing research, however this platform is particularly useful in complex histological findings and may help clinicians to guide the therapy.

Key words: kidney transplantation, gene expression, RT-qPCR, microarray, MMDx, molecular microscope

Introduction

Kidney transplantation is the treatment of choice for end-stage renal disease. Acute and chronic rejection represent the main obstacle for long-term outcomes (Sellares et al. 2012, Sis et al. 2010). Kidney graft rejection diagnostics was traditionally based on clinical and histological criteria. The Banff classification was introduced to improve and standardise histological diagnostics for transplanted organs (Solez et al. 1993). However, histology is descriptive in principle and limited to semi-quantitative assessment only. Therefore, similar morphologies may actually reflect non-homogenous cohorts with different outcomes. A better understanding of the mechanisms behind kidney graft rejection could yield novel preventive, diagnostic, and therapeutic approaches. Transcriptomics is an innovative tool used in several medical disciplines, including transplantation (Halloran et al. 2014). Assessment of molecular disturbances has already been incorporated into the Banff classification of kidney allograft pathology (Haas et al. 2014, Loupy et al. 2017, Haas et al. 2018). This review summarises the updated developments on molecular pathology in kidney transplantation.

Limitations of traditional diagnostic tools

Kidney grafts can be affected by nephrotoxicity, infections, vascular pathology, as well as transmitted, recurrent, or de novo diseases, among which the rejection is the most important. Two types of kidney allograft rejection have been recognized, T-cell-mediated (TCMR) and antibody-mediated rejection (ABMR). TCMR and ABMR differ in terms of pathogenesis, pathology, and prognosis, require tailored treatment, and cannot be distinguished exclusively based on clinical data (Sa et al. 2016). Recently, as the main cause of kidney allograft loss in the long-term follow the ABMR has been considered (Sellares et al. 2012, Sis et al. 2010).

Histologically, TCMR is distinguished from ABMR by the presence of mononuclear tubulitis and interstitial inflammation while microvascular inflammation, arteritis, acute tubular injury or thrombotic microangiopathy are observed in the latter case (Cornell 2016, Haas et al. 2018). The presence of complement component C4d in the peritubular capillaries reflects antibody-endothelium interaction (Cornell 2016, Haas et al. 2018) in ABMR. However, C4d assay has poor reproducibility (Mengel et al. 2013). C4d staining results may vary from negative (which does not exclude ABMR), to diffuse positive, and depend on method used (Cornell 2016, Haas et al. 2014, Sis et al. 2010). Arteritis and glomerulitis may occur in both ABMR and TCMR (Cornell 2016), or may not be associated with rejection (Cornell 2016). Tubulitis with interstitial inflammation can be a feature of tubulointerstitial nephritis regardless of aetiology. Despite TCMR, tubulointerstitial inflammation may be borderline, although in other patients borderline changes can be benign (Hruba et al. 2015). Similarly, double contours are not entirely unique to transplant glomerulopathy (TG) in chronic ABMR, as they also occur in chronic thrombotic microangiopathy and recurrent or de novo immune complex glomerulonephritis (Cornell 2016). Furthermore, kidney grafts can undergo mixed rejection or a combination of several pathologies, especially at a late post-transplant stage.

Histology assessment is greatly influenced by sample size. On the issue of sampling error, the Banff community recommends the examination of two cores containing the renal allograft

cortex (Racusen et al. 1999). Histological lesions are graded semi-quantitatively using arbitrarily defined grades. Criteria for the diagnoses rely on empirical rules and are the result of consensus (Roufosse et al. 2018). All of these factors have led to insufficient inter-observer reproducibility for lesion scoring and diagnosis, potentially resulting in inappropriate treatment (Furness and Taub 2001, Mengel et al. 2007, Halloran et al. 2014, Broecker and Mengel 2015, Solez and Racusen 2013, Smith et al. 2019). The lack of independent validation is another recognised pitfall in the histological Banff classification (Mengel et al. 2007).

Potential of molecular diagnostics

Initially, RT-PCR evaluation of single transcripts or subsets of several transcripts associated with T-cell or cytokine burden were performed in small patient cohorts. Studies showed associations of acute rejection with higher mRNA expressions of several cytokines (Krams et al. 1992), Toll-like receptors (Dessing et al. 2010), as well as of chronic graft injury with profibrogenic cytokines and chemokines (Hribova et al. 2007), and of therapy-resistant rejection with Fas ligand gene expression (Nickel et al. 2001). Moreover, lower expression of regulatory transcripts FOXP3 and CD20 was shown to be associated with the inferior outcome of early acute rejection (Viklicky et al. 2010).

With the development of microarray technology, a large-scale analysis of transcriptomic data was carried out. Using microarray analysis in diagnostic and protocol kidney allograft biopsies, Sarwal et al. (2003) was the first who provided evidence of molecular heterogeneity of renal allograft rejection with respect to pathogenesis, clinical course, and response to treatment.

In parallel with microarray, the development of more quantitative and sensitive RNA-sequencing technologies has led to the evaluation of differential gene expression in a much broader dynamic range than microarrays. In their proof-of-concept discovery study, Kurian et al. (2017) compared Affymetrix Gene Arrays and RNA-Seq using transplant biopsies from patients with stable allograft and with acute rejection. Both platforms demonstrated equivalent predictive performance. Despite the promising potential of sequencing, the studies published thus far on the use of RNA-Seq for detecting differentially expressed genes in kidney allografts are scarce and limited to small sample sizes (Dziubianau et al. 2013, Jeon et al. 2017).

Transcriptomic profiling of kidney graft biopsies provided some new information in clinically unclear cases (Halloran, Reeve et al. 2017, Halloran, Famulski et al. 2017, Reeve et al. 2016) and revealed transcripts associated with disease progression (Kadota et al. 2015, Hruba et al. 2015, Lefaucheur et al. 2018). Compared to semi-quantitative histology assessment, transcriptomic results are not only quantitative but demonstrate higher specificity (Sis et al. 2009, Naesens et al. 2011, Reeve et al. 2016, Halloran et al. 2014). The other advantage of molecular assessment is the ability to adequately assess small tissue samples (3 mm in length) independently of proportion of cortex/medulla (Madill-Thomsen et al. 2017), at least regarding molecular scores for ABMR, TCMR, and injury, but the impact of sample size on variability should be further explored (Halloran et al. 2017).

Microarray-derived molecular scores for ABMR and TCMR have been used to re-evaluate histological and serological criteria for rejection (Halloran, Famulski et al. 2017, Reeve et al. 2016). Molecular assessment of transcripts indicative of endothelial injury (Sis et al. 2010) in renal allografts was first added as a potential diagnostic criterion for ABMR to the Banff classification in 2013 (Haas et al. 2014). Findings on changes to endothelial transcripts, which can help to identify kidneys undergoing antibody-mediated injury, led to the inclusion of C4d-negative cases among ABMR categories (Sis et al. 2009). Transcriptomic data can therefore significantly improve diagnosis, prognosis, and prediction in kidney transplant settings.

Clearly, transcriptomic analyses cannot distinguish the source of gene transcripts when a part of the biopsy is stored in RNA later which dissolve the tissue structure. Composition of the sample, e.g. the presence of glomeruli or the amount of fibrotic or inflamed tissue, also ultimately impacts on gene expression. Kidney compartment-specific expression can be satisfactorily assessed using laser-capture microdissection (Cohen et al. 2002, Serinsöz et al. 2005, Blakey and Laszik 2004, Tycova et al. 2018). However, tissue processing during laser microdissection requires careful handling to preserve RNA integrity. Obtaining a reasonable amount of microdissected compartments to isolate RNA of sufficient quantity represents also a great challenge. Tissue for microdissection can either be snap-frozen (Tycova et al. 2018) or fixed and then paraffin-embedded (Fries et al. 2003, Schmid et al. 2003, Bockmeyer et al. 2018). However, RNA yields are much higher from cryosections (Cohen at al. 2002). According to our study, RNA obtained from 10 microdissected 10 micrometre-thick kidney glomeruli is sufficient for measuring around 10 transcripts by RT-qPCR (Tycova et al. 2018). Compartment-specific gene expression may help to identify the mechanisms involved in particular pathological processes (Seeger et al. 2018).

Molecular microscope: past, present, and future

Large-scale data generated by microarray require sophisticated statistical tools to extract biologically meaningful information. Based on the premise that transcript sets better reflect ongoing processes in kidney allograft than single transcripts, Halloran et al. introduced a definition for pathogenesis-based transcript sets (PBTs) **(Table 1)**. The first graft pathology-related PBTs to be defined were based on experimental mouse kidney transplants (IFN-γ and rejection-induced transcripts – GRIT) (Famulski et al. 2006) and cell cultures (T- and B cell-associated transcripts) (Hidalgo et al. 2012, Einecke et al. 2008). One study reported higher PBT scores in 143 consecutive human kidney transplant indication biopsies during rejection, notwithstanding similar ABMR and TCMR scores (Mueller et al. 2007). Sis et al. (2009) showed that expression of 119 endothelial-associated transcripts (selected based on the literature) was higher in ABMR than in TCMR, correlated with histopathological ABMR lesions, and predicted graft loss. Hidalgo et al. (2010) proposed a set of donor-specific antibody (DSA)-selective transcripts (DSASTs). Further studies by the Halloran group significantly expanded the list of PBTs to reflect the major biological allograft processes (https://www.ualberta.ca/medicine/institutes-centres-groups/atagc/research/gene-lists). A comparison of 75 most ABMR-selective transcripts derived from the INTERCOMEX Study with DSA-, endothelial cell-associated transcripts (ENDAT-), and C1q-binding anti-HLA DSA-PBT sets showed that 17 transcripts were DSA-selective (22.6%), 14 (18.7%) were endothelial-

associated, and 2 transcripts (LST1 and FCGR3A) were complement-binding DSA-selective-associated (**Figure 1**).

The advantage and validity of the PBT concept have been further confirmed by other groups. Using the same approach, Lubetzky et al. (2019) compared 49 patients with TG and microvascular inflammation to 51 patients with TG but no microvascular inflammation. Transplant glomerulopathy with microvascular inflammation had increased expression of IFN-γ and rejection-induced transcripts and DSAST resembling ABMR, while TG biopsies without microvascular inflammation exhibited increased expression of cytotoxic and regulatory T cells and B cells, indicating TCMR.

Following PBTs, the Edmonton group developed several classifiers for particular kidney allograft pathologies, starting with ABMR and TCMR (Reeve et al. 2013, Sellares et al. 2013) **(Table 1)**. Both classifiers were developed based on microarray profiling of 403 indication kidney graft biopsies. The TCMR classifier was built by comparing 35 histologically confirmed TCMR cases versus all other diagnoses, while the ABMR classifier was built by comparing both C4d-positive and C4d-negative ABMR (n=65) cases versus all other cases. Using linear discriminant analysis, the classifiers assigned an ABMR or TCMR score between 0 and 1.0 to each biopsy. The TCMR cut-off score (>0.1) resulted in 50% sensitivity and 95% specificity for TCMR diagnosis. The top 30 genes selected by the classifier algorithm were either primarily expressed in effector T cells and myeloid cells or were IFN-γ-inducible. The ABMR cut-off score (>0.2) resulted in 90% specificity and 67% sensitivity for ABMR diagnosis. The top 30 genes selected using the ABMR classifier algorithm were primarily endothelial, in addition to genes reflecting IFN-γ effects, or presence of NK cells and myeloid cells.

The diagnostic performance of these newly developed molecular classifiers for ABMR and TCMR was validated by the prospective INTERCOM study, comprising six international centres (Halloran et al. 2013, Halloran et al. 2013) working with a central diagnostic system – the Molecular Microscope Diagnostic System® (MMDx) – at Alberta Transplant Applied Genomics Centre. MMDx compares gene expression data for a given biopsy to a reference set of samples, assigning probabilistic quantitative scores to diagnose rejection, acute parenchymal injury (Famulski et al. 2012), atrophy/fibrosis (Venner et al. 2016), and non-adherence (Einecke et al. 2018), or to predict progression to failure (Einecke et al. 2010, Loupy et al. 2014) **(Table 1)**. For each biopsy, a summary of molecular changes, reference values, and interpretative analysis are provided. However, classifiers were developed and validated mainly in indication biopsies performed early or late after transplantation (Reeve et al. 2019) and its performance in protocol biopsies to reveal subclinical rejection still needs to be validated. The feasibility of MMDx as a real-time central molecular assessment system for kidney transplant biopsy samples was further evaluated by the prospective INTERCOMEX study, which analysed 519 biopsies from 10 centres in North American and Europe. Automated reports were generated based exclusively on MMDx classifier algorithms without knowledge of histologies or HLA antibodies (Halloran, Reeve et al. 2017). RNA quality and yield were almost uniformly high, 96% of biopsy samples were readable, and agreement between MMDx and histology exceeded 75%. The authors concluded that real time central molecular assessment is feasible, the report satisfied clinicians' expectations more often than local

histological assessment, and provided more weighted information for clinical decision-making.

MMDx overcomes several of the acknowledged limitations associated with microarray. The issue of insufficient reproducibility (Akalin and O'Connell 2010, Khatri et al. 2009, Halloran et al. 2014) was resolved using one microarray platform performed according to standard procedure at a single centre. Final scores were obtained using a large, fully phenotyped reference set in tandem with robust data analysis combining 12 different classifiers. Moreover, published data supported the notion that precision and accuracy of MMDx outperformed those of histology (Reeve et al. 2019).

Applying molecular ABMR scores permits the reassessment of histological and serological ABMR criteria (**Table 1**). Peritubular capillaritis, glomerulitis, glomerular double contours, DSA, and C4d staining are important features for ABMR diagnosis, whereas other Banff-recognised lesions demonstrate little (arteritis, arterial fibrous intimal thickening) or no (thrombotic microangiopathy, acute tubular injury, scarring) importance (Halloran, Famulski et al. 2017). Similarly, interstitial infiltrate and tubulitis are acknowledged as key histological predictors of molecular TCMR, with arteritis deemed less important (Reeve et al. 2016). In indication biopsies, i-IFTA is associated more with molecular injury and ABMR than with molecular TCMR (Halloran et al. 2018).

MMDx can complement histological criteria provided they fall under the threshold for rejection diagnosis, or prove discordant with immunopathological or serological criteria (**Table 2**). However, some limitations of MMDx have been exposed. Stereotyped changes in microarray may not be entirely disease-specific. Given the small amount of tissue sampled, the heterogeneous cellular composition of the biopsy may theoretically impact on results (Akalin and O'Connell 2010). Focal changes (e.g. glomerular) tend to be evaluated less reliably than diffuse changes (Halloran et al. 2014, Halloran et al. 2015), while not all graft diseases might be evaluated accurately (e.g. glomerulonephritis, vascular and infectious pathology). It is unclear how inflammatory infiltrates in tubulointerstitial nephritis can be differentiated from acute rejection. Since MMDx is not a universal tool, non-rejection transplant pathology up to date can be better diagnosed with standard of care methods (e.g., light and fluorescent microscopy, and EM for glomerulonephritis, IHC for polyoma large T antigen, EM for viral particles and plasma PCR screen for viral load in case of suspected polyoma BK nephropathy). However, MMDx can help to exclude rejection when it is mixed with other pathology of the graft. In addition to rejection scores MMDx comprises acute kidney injury, inflammation, atrophy-fibrosis, and adherence scores that can help diagnose non-rejection transplant pathologies as well.

Prospective multicenter validation studies comparing MMDx-guided therapy with standard of care would help to strengthen the clinical significance of this new diagnostic tool and contribute to its routine adoption to clinical praxis. Moreover, in view of growing number of non-invasive molecular biomarkers for kidney graft evaluation (Suthanthiran et al. 2013, Roedder et al. 2014, Christakoudi et al. 2019; Huang et al. 2019) it will be interesting to compare diagnostic and prognostic performance of molecular microscope vs those molecular biomarkers.

Conclusion

During past several decades molecular assessment of kidney allograft has made striking progress, from evaluation of a single gene or their sets through PBTs and molecular classifiers to MMDx. High sensitivity and specificity of molecular scores have been used to improve histological and serological criteria for graft pathology. Integrating histological, serological, and molecular assessment of renal allografts may thus provide more accurate diagnostics to improve outcome of kidney transplantation.

Table 1. Molecular microscope body of evidence

Reference	No. of biopsies	Main findings
Development of PBTs		
Mueller et al. 2007	143, diagnostic	PBTs representing three biological processes in graft rejection (cytotoxic T-cell infiltration (QCAT), IFNG effects (GRIT1), and parenchymal deterioration (KT) increased in biopsies with rejection (TCMR, ABMR, mixed) compared to non-rejection biopsies.
Sis et al. 2009	173, diagnostic	Literature-based endothelium-associated transcripts (ENDATs, n=119) of which 25 were differentially expressed between C4d+ABMR and TCMR (e.g. VWF, CAV1, RHOJ, MCAM, CDH5, SELE).
Hidalgo et al. 2010	145, diagnostic	DSAST: higher expression in DSA+ biopsies compared to DSA-.
Development of classifiers		
Sellarés et al., 2013	403, diagnostic	A molecular classifier for ABMR was built based on the top 30 differentially expressed genes between ABMR and other biopsies (e.g. CDH13, CXCL11, DARC PLA1A, ROBO4, KLF4, TM4SF18, GNG11).
Reeve et al., 2013	403, diagnostic	A molecular classifier for TCMR was built based on the top 30 differentially expressed genes between TCMR and other biopsies (e.g. CD96, SIRPB2, TNFSF8, BTLA, OR2I1P, IL21R).
Famulski et al., 2012	37, protocol, diagnostic	A molecular classifier for AKI was built based on the top 30 differentially expressed genes between pure AKI indication biopsies (n=28) and stable protocol biopsies (n=11), including ITGB6, SERPINA3, MTND6, OLFM4, PTX3, LCN2a, VCAN.
Einecke et al., 2010	105, diagnostic	A molecular classifier for predicting graft loss was built based on the top 30 differentially expressed transcripts between grafts failed within 32 months after for-cause biopsy and non-failed grafts (e.g. ITGB6, HAVCR1, LTF, ADAMTS1, SERPINA3, NNMT, and VCAN).
Venner et al., 2016	681, diagnostic	A molecular classifier for atrophy/fibrosis was built based on the top 30 differentially expressed genes between early biopsies with no fibrosis ($ci≤1$) and late biopsies with fibrosis ($ci>1$), including ITGB6, MIR21, VCAN, NNMT, and CPA3.
Einecke et al., 2018	562, diagnostic	A molecular classifier used to predict hyalinosis at a given time post-transplant was built based on the top 30 differentially expressed genes between biopsies with ah=0 and ah>0 with time correction, including APOBEC3G, HLA-G, BTN3A1, CXCL13, OR2I1P, PSMB8, ITGB6, MIR21, VCAN, NNMT, CPA3GCNT1, CD8B1, RAP2B, IL10RB, and CNPY3.
Validation of MMDx		
Halloran et al., 2013	300, diagnostic	In the INTERCOM Study (6 centres), TCMR scores correlated with histological TCMR lesions (tubulitis and interstitial inflammation). A TCMR score >0.1 predicted TCMR diagnosis with an accuracy of 87%, similar to the reference set (89%).
Halloran et al., 2013	300, diagnostic	In the INTERCOM Study (6 centres), molecular ABMR diagnosis was predicted by histology-based diagnosis in 59 % of biopsies only. ABMR scores correlated with histological ABMR lesions and DSA. An ABMR score >0.2 predicted the diagnosis of ABMR or mixed rejection with an accuracy of 85% (identical to the reference set and local assessment).
Halloran et al., 2017	538, diagnostic	In the INTERCOMEX Study (10 centres), MMDx was verified in real-time. Agreement between MMDx and histology was 77% for TCMR, 77% for ABMR, and 76% for no rejection. Despite MMDx and histology results differing in 24% of biopsy samples, clinicians disagreed more often with histology than with MMDX.
MMDx as a tool to refine histological criteria		
Halloran et al., 2017	703, diagnostic	ABMR-positive MMDx scores correlated mainly with peritubular capillaritis, glomerulitis, glomerular double contours, DSA, and C4d staining, but much less with arterial fibrosis and vasculitis.
Reeve et al., 2016	703, diagnostic	TCMR-positive MMDx scores correlated mainly with interstitial infiltrate and tubulitis, but less with arteritis (v-lesion).

Halloran et al., 2018	238, diagnostic	ABMR was diagnosed in 45% of i-IFTA biopsies with MMDx and in only 28% based on histology. TCMR was diagnosed in 16% of i-IFTA biopsies with MMDx and in only 8% based on histology. The prominent feature of i-IFTA biopsies was molecular injury (e.g. acute kidney injury transcripts), which predicted graft loss.

PBTs: pathogenesis-based transcript sets, IFNG: interferon gamma, TCMR: T cell-mediated rejection, ABMR: antibody-mediated rejection, DSA: donor-specific antibody, DSAST: DSA-selective transcripts, AKI: acute kidney injury, MMDx: molecular microscope diagnostic system, i-IFTA: inflammation in areas of interstitial fibrosis-tubular atrophy

Table 2. Examples of diagnostics pitfalls potentially resolved by using molecular methods

Difficult diagnoses	Histology (Banff score)	Immunohistology + serology
Active ABMR vs. no active ABMR	1. MVI ≥ 1 2. ATI, in the absence of any other apparent cause, MVI < 2 3. Acute TMA, in the absence of any other cause, MVI < 2 4. v > 0, MVI < 2	C4d-negative, DSA-positive
	1. MVI ≥ 2 2. v > 0, MVI < 2	C4d-negative, DSA-negative
	MVI 0	C4d-positive, DSA ±
Chronic active ABMR vs. no chronic active ABMR	1. cg > 0, MVI < 2 2. Severe PTCBMML, MVI < 2 3. AIF of new onset, excluding other causes, MVI < 2	C4d-negative, DSA-positive
Acute TCMR vs. no rejection	1. v > 0, MVI < 2, t 0, i 0 2. BL, i.e. under diagnostic threshold for rejection (t ≥ 2 and i ≥ 2)	C4d-negative, DSA-negative
Pure TCMR I or BL vs. mixed rejection	g 0, ptc ≥1, acute TCMR I or BL	C4d-negative, DSA-positive
Pure TCMR II–III vs. mixed rejection	v > 0, MVI <2	C4d-negative, DSA ±
Isolated BKVN vs. coincident with TCMR	t 2-3, i 2-3	C4d-negative, SV40-positive DSA-negative

ABMR: antibody-mediated rejection, AIF: arterial intimal fibrosis, ATI: acute tubular injury, BL: borderline lesions, BKVN: BK virus nephropathy, DSA: donor-specific antibodies, MVI: microvascular inflammation (g+ptc) score, TCMR: T cell-mediated rejection, PTCBMML: peritubular capillary basement membrane multilayering, TMA: thrombotic microangiopathy, cg: glomerular basement membrane double contour score, v: arteritis score, t: tubulitis score, i: interstitial inflammation score, g: glomerulitis score, ptc: peritubular capillaritis score, SV40: simian virus antigen 40.

Figure 1. The top 75 ABMR-selective transcripts derived from THE INTERCOMEX Study (Halloran, Reeve et al. 2017) were compared with particular PBTs using Venn diagrams. (http://bioinformatics.psb.ugent.be/webtools/Venn/). C1q-binding DSA PBT (Lefaucheur et al. 2018), DSA PBT (Hidalgo et al. 2010), ENDAT PBT (Sis et al. 2009).

References

AKALIN E, O'CONNELL PJ: Genomics of chronic allograft injury. *Kidney Int* **78**: S33–S37, 2010.

BLAKEY GL, LASZIK ZG: Laser-assisted microdissection of the kidney: Fundamentals and applications. *J Mol Histol* **35**: 581–587, 2004.

BOCKMEYER CL, WITTIG J, SÄUBERLICH K, SELHAUSEN P, EßER M, ZEUSCHNER P, MODDE F, AMANN K, DANIEL C: Recommendations for mRNA analysis of micro-dissected glomerular tufts from paraffin-embedded human kidney biopsy samples. *BMC Mol Biol*. **19**: 2, 2018.

BROECKER V, MENGEL M: The significance of histological diagnosis in renal allograft biopsies in 2014. *Transplant Int* **28**: 136–145, 2015.

CHRISTAKOUDI S, RUNGLALL M, MOBILLO P, TSUI T, DUFF C, DOMINGO-VILA C, KAMRA Y, DELANEY F, MONTERO R, SPIRIDOU A, KASSIMATIS T, PHIN-KON S, TUCKER B, FARMER C, STROM TB, LORD GM, REBOLLO-MESA I, STAHL D, SACKS S, HERNANDEZ-FUENTES MP, CHOWDHURY P: Development of a multivariable gene-expression signature targeting T-cell-mediated rejection in peripheral blood of kidney transplant recipients validated in cross-sectional and longitudinal samples. *EBioMedicine* **41:** 571–583, 2019.

COHEN CD, GRONE HJ, GRONE EF, NELSON PJ, SCHLONDORFF D, KRETZLER M: Laser microdissection and gene expression analysis on formaldehyde-fixed archival tissue. *Kidney Int* **61**: 125–132, 2002.

CORNELL LD: Rejection. In: Diagnostic Pathology: Kidney Diseases. COLVIN RB, CHANG A (eds.), Elsevier, Philadelphia, 2016, pp. 948–980.

DESSING MC, BEMELMAN FJ, CLAESSEN N, TEN BERGE IJ, FLORQUIN S, LEEMANS JC: Intragraft Toll-like receptor profiling in acute renal allograft rejection. *Nephrol Dial Transplant* **25:** 4087–4092, 2010.

DZIUBIANAU M, HECHT J, KUCHENBECKER L, SATTLER A, STERVBO U, RODELSPERGER C, NICKEL P, NEUMANN AU, ROBINSON N, MUNDLOS S, VOLK HD, THIEL A, REINKE P, BABEL N: TCR repertoire analysis by next generation sequencing allows complex differential diagnosis of T cell-related pathology. *Am J Transplant* **13**: 2842–2854, 2013.

EINECKE G, REEVE J, HALLORAN PF: A molecular biopsy test based on arteriolar under-hyalinosis reflects increased probability of rejection related to under-immunosuppression. *Am J Transplant* **18**: 821–831, 2018.

EINECKE G, REEVE J, MENGEL M, SIS B, BUNNAG S, MUELLER TF, HALLORAN PF: Expression of B cell and immunoglobulin transcripts is a feature of inflammation in late allografts. *Am J Transplant* **8**:1434–1443, 2008.

EINECKE G, REEVE J, SIS B, MENGEL M, HIDALGO L, FAMULSKI KS, MATAS A, KASISKE B, KAPLAN B, HALLORAN PF: A molecular classifier for predicting future graft loss in late kidney transplant biopsies. *J Clin Invest* **120**: 1862–1872, 2010.

FAMULSKI KS, EINECKE G, REEVE J, RAMASSAR V, ALLANACH K, MUELLER T, HIDALGO LG, ZHU LF, HALLORAN PF: Changes in the transcriptome in allograft rejection: IFN-gamma-induced transcripts in mouse kidney allografts. *Am J Transplant* **6**: 1342–1354, 2006.

FAMULSKI KS, DE FREITAS DG, KREEPAL CI, CHANG J, SELLARES J, SIS B, EINECKE G, MENGEL M, REEVE J, HALLORAN PH: Molecular phenotypes of acute kidney injury in kidney transplants. *J Am Soc Nephrol* **23:** 948–958, 2012.

FRIES JW, ROTH T, DIENES HP, WEBER M, ODENTHAL M: A novel evaluation method for paraffinized human renal biopsies using quantitative analysis of microdissected glomeruli and VCAM-1 as marker of inflammatory mesangial cell activation. *Nephrol Dial Transplant* **18**: 710-716, 2003.

FURNESS PN, TAUB N: International variation in the interpretation of renal transplant biopsies: Report of the CERTPAP Project. *Kidney Int* **60**: 1998–2012, 2001.

HAAS M, LOUPY A, LEFAUCHEUR C, ROUFOSSE C, GLOTZ D, SERON D, NANKIVELL BJ, HALLORAN PF, COLVIN RB, AKALIN E, ALACHKAR N., BAGNASCO S, BOUATOU Y, BECKER JU, CORNELL LD, DUONG VAN HUYEN JP, GIBSON IW, KRAUS ES, MANNON RB, NAESENS M, NICKELEIT V, NICKERSON P, SEGEV DL, SINGH HK, STEGALL M, RANDHAWA P, RACUSEN L, SOLEZ K, MENGEL M: The Banff 2017 kidney meeting report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. *Am J Transplant* **18**: 293–307, 2018.

HAAS M, SIS B, RACUSEN LC, SOLEZ K, GLOTZ D, COLVIN RB, CASTRO MCR, DAVID DSR, DAVID-NETO E, BAGNASCO SM, CENDALES LC, CORNELL LD, DEMETRIS AJ, DRACHENBERG CB, FARVER CF, FARRIS AB, GIBSON IW, KRAUS E, LIAPIS H, LOUPY A, NICKELEIT V, RANDHAWA P, RODRIGUEZ ER, RUSH D, SMITH RN, TAN CD, WALLACE WD, MENGEL M: Banff 2013 meeting report: Inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. *Am J Transplant* **14**: 272–283, 2014.

HALLORAN PF, FAMULSKI K, REEVE J: The molecular phenotypes of rejection in kidney transplant biopsies. *Curr Opin Organ Transplant* **20**: 359–367, 2015.

HALLORAN PF, FAMULSKI K, CHANG J: A probabilistic approach to histologic diagnosis of antibody-mediated rejection in kidney transplant biopsies. *Am J Transplant* **17**: 129–139, 2017.

HALLORAN PF, PEREIRA AB, CHANG J, MATAS A, PICTON M, DE FREITAS D, BROMBERG J, SERON D, SELLARES J, EINECKE G, REEVE J: Potential impact of microarray diagnosis of T cell-mediated rejection in kidney transplants: The INTERCOM Study. *Am J Transplant* **13**: 2352–2363, 2013.

HALLORAN PF, PEREIRA AB, CHANG J, MATAS A, PICTON M, DE FREITAS D, BROMBERG J, SERON D, SELLARES J, EINECKE G, REEVE J: Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: An international prospective study (INTERCOM). *Am J Transplant* **13**: 2865–2874, 2013.

HALLORAN PF, REEVE JP, PEREIRA AB, HIDALGO LG, FAMULSKI KS: Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: New insights from the Genome Canada studies of kidney transplant biopsies. *Kidney Int* **85**: 258–264, 2014.

HALLORAN PF, REEVE J, AKALIN E, AUBERT O, BOHMIG GA, BRENNAN D, BROMBERG J, EINECKE G, ESKANDARY F, GOSSET C, DUONG VAN HUYEN J.-P, GUPTA G, LEFAUCHEUR C, MALONE A, MANNON RB, SERON D, SELLARES J, WEIR M, LOUPY A: Real time central assessment of kidney transplant indication biopsies by microarrays: The INTERCOMEX Study. *Am J Transplant* **17**: 2851–2862, 2017.

HALLORAN PF, MATAS A, KASISKE BL, MADILL-THOMSEN KS, MACKOVA M, FAMULSKI KS: Molecular phenotype of kidney transplant indication biopsies with inflammation in scarred areas. *Am J Transplant* **18**: 1–15, 2018.

HIDALGO LG, SIS B, SELLARES J, CAMPBELL PM, MENGEL M, EINECKE G, CHANG J, HALLORAN PF: NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: Evidence for NK cell involvement in antibody-mediated rejection. *Am J Transplant* **10**: 1812–1822, 2010.

HIDALGO LG, SELLARES J, SIS B, MENGEL M, CHANG J, HALLORAN PF: Interpreting NK cell transcripts versus T cell transcripts in renal transplant biopsies. *Am J Transplant* **12**: 1180–1191. 2012.

HRIBOVA P, LACHA J, KOTSCH K, VOLK HD, BRABCOVA I, SKIBOVA J, VITKO S, VIKLICKY O: Intrarenal cytokine and chemokine gene expression and kidney graft outcome. *Kidney Blood Press Res.* **30**: 273–282, 2007.

HRUBÁ P, BRABCOVÁ I, GUELER F, KREJČÍK Z, STRÁNECKÝ V, SVOBODOVÁ E, MALUŠKOVÁ J, GWINNER W, HONSOVÁ E, LODEREROVÁ A, OBERBAUER R, ZACHOVAL R, VIKLICKÝ O: Molecular diagnostics identifies risks for graft dysfunction despite borderline histologic changes. *Kidney Int* **88**: 785–795, 2015.

HUANG E, SETHI S, PENG A, NAJJAR R, MIROCHA J, HAAS M, VO A, JORDAN SC: Early clinical experience using donor-derived cell-free DNA to detect rejection in kidney transplant recipients. *Am J Transplant* **19:** 1663-1670, 2019.

JEON HJ, KIM K, LEE JG, JANG JY, CHOI S, FANG T, YAN JJ, HAN M, JEONG JC, LEE KB, KIM TJ, AHN C, YANG J: VDJ gene usage among B-cell receptors in ABO-incompatible kidney transplantation determined by RNA-seq transcriptomic analysis. *BMC Nephrol* **18**: 340, 2017.

KADOTA PO, HAJJIRI Z, FINN PW, PERKINS DL: Precision subtypes of T cell-mediated rejection identified by molecular profiles. *Front Immunol* **6**: 536, 2015.

KHATRI P, SARWAL MM: Using gene arrays in diagnosis of rejection. *Curr Opin Organ Transplant* **14**: 34–39, 2009.

KRAMS SM, FALCO DA, VILLANUEVA JC, RABKIN J, TOMLANOVICH SJ, VINCENTI F, AMEND WJ, MELZER J, GAROVOY MR, ROBERTS JP: Cytokine and T cell receptor gene expression at the site of allograft rejection. *Transplantation* **53**: 151–156, 1992.

KURIAN SM, VELAZQUEZ E, THOMPSON R, WHISENANT T, ROSE S, RILEY N, HARRISON F, GELBART T, FRIEDEWALD JJ, CHARRETTE J, BRIETIGAM S, PEYSAKHOVICH J, FIRST MR, ABECASSIS MM, SALOMON DR: Orthogonal comparison of molecular signatures of kidney transplants with subclinical and clinical acute rejection: Equivalent performance is agnostic to both technology and platform. *Am J Transplant* **17:** 2103–2116, 2017.

LEFAUCHEUR C, VIGLIETTI D, HIDALGO LG, RATNER LE, BAGNASCO SM, BATAL I, AUBERT O, ORANDI BJ, OPPENHEIMER F, BESTARD O, RIGOTTI P, REISAETER AV, KAMAR N, LEBRANCHU Y, DUONG VAN HUYEN JP, BRUNEVAL P, GLOTZ D, LEGENDRE C, EMPANA JP, JOUVEN X, SEGEV DL, MONTGOMERY RA, ZEEVI A, HALLORAN PF, LOUPY A: Complement-activating anti-HLA antibodies in kidney transplantation: Allograft gene expression profiling and response to treatment. *J Am Soc Nephrol* **29**: 620–635, 2018.

LOUPY A, HAAS M, SOLEZ K, RACUSEN L, GLOTZ D, SERON D, NANKIVELL BJ, COLVIN RB, AFROUZIAN M, AKALIN E, ALACHKAR N, BAGNASCO S, BECKER JU, CORNELL L, DRACHENBERG C, DRAGUN D, DE KORT H, GIBSON IW, KRAUS ES, LEFAUCHEUR C, LEGENDRE C, LIAPIS H, MUTHUKUMAR T, NICKELEIT V, ORANDI B, PARK W, RABANT M, RANDHAWA P, REED EF, ROUFOSSE C, SESHAN SV, SIS B, SINGH HK, SCHINSTOCK C, TAMBUR A, ZEEVI A, MENGEL M: The Banff 2015 kidney meeting report: Current challenges in rejection classification and prospects for adopting molecular pathology. *Am J Transplant* **17**: 28–41, 2017.

LOUPY A, LEFAUCHEUR C, VERNEREY D, CHANG J, HIDALGO LG, BEUSCART T, VERINE J, AUBERT O, DUBLEUMORTIER S, DUONG VAN HUYEN JP, JOUVEN X, GLOTZ D, LEGENDRE C, HALLORAN PF:

Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. *J Am Soc Nephrol* **25**: 2267–2277, 2014.

LUBETZKY M, HAYDE N, Ó BROIN P, AJAIMY M, BAO Y, MOHAMMED O, SCHWARTZ D, PULLMAN J, AKALIN E: Molecular signatures and clinical outcomes of transplant glomerulopathy stratified by microvascular inflammation and donor-specific antibody. *Clin Transplant* **33**: e13469, 2019.

MADILL-THOMSEN KS, WIGGINS RC, ESKANDARY F, BÖHMIG GA, HALLORAN PF: The effect of cortex/medulla proportions on molecular diagnoses in kidney transplant biopsies: Rejection and injury can be assessed in medulla. *Am J Transplant* **17**: 2117–2128, 2017.

MENGEL M, CHAN S, CLIMENHAGA J, KUSHNER YB, REGELE H, COLVIN RB, RANDHAWA P: Banff initiative for quality assurance in transplantation (BIFQUIT): Reproducibility of C4d immunohistochemistry in kidney allografts. *Am J Transplant* **13**: 1235–1245, 2013.

MENGEL M, SIS B, HALLORAN PF: SWOT analysis of Banff: Strengths, weaknesses, opportunities and threats of the international Banff consensus process and classification system for renal allograft pathology. *Am J Transplant* **7**: 2221–2226, 2007.

MUELLER TF, EINECKE G, REEVE J, SIS B, MENGEL M, JHANGRI GS, BUNNAG S, CRUZB J, WISHART D, MENG C, BRODERICK G, KAPLAN B, HALLORAN PF: Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. *Am J Transplant* **7**: 2712–2722, 2007.

NAESENS M, KHATRI P, LI L, SIGDEL TK, VITALONE MJ, CHEN R, BUTTE AJ, SALVATIERRA O, SARWAL MM: Progressive histological damage in renal allografts is associated with expression of innate and adaptive immunity genes. *Kidney Int* **80**: 1364–1376, 2011.

NICKEL P, LACHA J, ODE-HAKIM S, SAWITZKI B, BABEL N, FREI U, VOLK HD, REINKE P: Cytotoxic effector molecule gene expression in acute renal allograft rejection: correlation with clinical outcome; histopathology and function of the allograft. *Transplantation* **72**: 1158–1160, 2001.

RACUSEN LC, SOLEZ K, COLVIN RB, BONSIB SM, CASTRO MC, CAVALLO T, CROKER BP, DEMETRIS AJ, DRACHENBERG CB, FOGO AB, FURNESS P, GABER LW, GIBSON IW, GLOTZ D, GOLDBERG JC, GRANDE J, HALLORAN PF, HANSEN HE, HARTLEY B, HAYRY PJ, HILL CM, HOFFMAN EO, HUNSICKER LG, LINDBLAD AS, YAMAGUCHI Y: The Banff 97 working classification of renal allograft pathology. *Kidney Int* **55:** 713–723, 1999.

REEVE J, BÖHMIG GA, ESKANDARY F, EINECKE G, GUPTA G, MADILL-THOMSEN K, MACKOVA M, | HALLORAN PH: Generating automated kidney transplant biopsy reports combining molecular measurements with ensembles of machine learning classifiers. *Am J Transplant* **19:** 2719–2731, 2019.

REEVE J, CHANG J, SALAZAR IDR, LOPEZ MM, HALLORAN PF: Using molecular phenotyping to guide improvements in the histologic diagnosis of T cell–mediated rejection. *Am J Transplant* **16**: 1183–1192, 2016.

REEVE J, SELLARES J, MENGEL M, SIS B, SKENE A, HIDALGOA L, DE FREITASD DG, FAMULSKI KS, HALLORAN PF: Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. *Am J Transplant* **13**: 645–655, 2013.

ROEDDER S, SIGDEL T, SALOMONIS N, HSIEH S, DAI H, BESTARD O, METES D, ZEEVI A, GRITSCH A, CHEESEMAN J, MACEDO C, PEDDY R, MEDEIROS M, VINCENTI F, ASHER N, SALVATIERRA O, SHAPIRO R, KIRK A, REED EF, SARWAL MM: The kSORT assay to detect renal transplant patients at high risk for acute rejection: results of the multicenter AART study. *PLoS Med.* **11**: e1001759, 2014.

ROUFOSSE C, SIMMONDS N, CLAHSEN-VAN GRONINGEN M, HAAS M, HENRIKSEN KJ, HORSFIELD C, LOUPY A, MENGEL M, PERKOWSKA-PTASIŃSKA A, RABANT M, RACUSEN LC, SOLEZ K, BECKER JU: A 2018 Reference guide to the Banff classification of renal allograft pathology. *Transplantation* **102:** 1795–1814, 2018.

SÁ H, LEAL R, SANTOS ROSA M: Renal transplant immunology in the last 20 years: A revolution towards graft and patient survival improvement. *Int Rev Immunol* **36**: 182–203, 2017.

SARWAL M, CHUA MS, KAMBHAM N, HSIEH SC, SATTERWHITE T, MASEK M, SALVATIERRA O JR: Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. *N Engl J Med* **349**: 125–138, 2003.

SCHMID H, HENGER A, COHEN CD, FRACH K, GRONE H-J, SCHLONDORFF D, KRETZLER M: Gene expression profiles of podocyte-associated molecules as diagnostic markers in acquired proteinuric diseases. *J Am Soc Nephrol* **14:** 2958–2966, 2003.

SEEGER H, LINDENMEYER MT, COHEN CD, JAECKEL C, NELSON PJ, CHEN J, EDENHOFER I, KOZAKOWSKI N, REGELE H, BOEHMIG G, BRANDT S, WUETHRICH RP, HEIKENWALDER M, FEHR T, SEGERER S: Lymphotoxin expression in human and murine renal allografts. *PLoS ONE* **13**: e0189396, 2018.

SELLARÉS J, DE FREITAS DG, MENGEL M, REEVE J, EINECKE G, SIS B, HIDALGO LG, FAMULSKI K, MATAS A, HALLORAN PF: Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. *Am J Transplant* **12**: 388–399, 2012.

SELLARES J, REEVE J, LOUPY A, MENGEL M, SIS B, SKENE A, DE FREITAS D, KREEPALA C, HIDALGO LG, FAMULSKI KS, HALLORAN PF: Molecular diagnosis of antibody-mediated rejection in human kidney transplants. *Am J Transplant* **13**: 971–983, 2013.

SERINSOZ E, BOCK O, GWINNER W, SCHWARZ A, HALLER H, KREIPE H, MENGEL M: Local complement C3 Expression is upregulated in humoral and cellular rejection of renal allografts. *Am J Transplant* **5:** 1490–1494, 2005.

SIS B, MENGEL M, HAAS M, COLVIN RB, HALLORAN PF, RACUSEN LC, SOLEZ K, BALDWIN III WM, BRACAMONTE ER, BROECKER V, COSIO F, DEMETRIS AJ, DRACHENBERG C, EINECKE G, GLOOR J, GLOTZ D, KRAUS E, LEGENDRE C, LIAPIS H, MANNON RB, NANKIVELL BJ, NICKELEIT V, PAPADIMITRIOU JC, RANDHAWA P, REGELE H, RENAUDIN K, RODRIGUEZ ER, SERON D, SESHAN S, SUTHANTHIRAN M, WASOWSKA BA, ZACHARY A, ZEEVI A: Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. *Am J Transplant* **10**: 464–471, 2010.

SIS B, JHANGRI GS, BUNNAG S, ALLANACH K, KAPLAN B, HALLORAN PF: Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. *Am J Transplant* **9**: 2312–2323, 2009.

SMITH B, CORNELL LD, SMITH M, CORTESE C, GEIGER X, ALEXANDER MP RYAN M, PARK W, MORALES ALVAREZ MC, SCHINSTOCK C, KREMERS W, STEGALL M: A method to reduce variability in scoring antibody-mediated rejection in renal allografts: Implications for clinical trials – a retrospective study. *Transpl Int* **32**: 173–183, 2019.

SOLEZ K, AXELSEN RA, BENEDIKTSSON H, BURDICK JF, COHEN AH, COLVIN RB, CROKER BP, DROZ D, DUNNILL MS, HALLORAN PF, HAYRY P, JENNETTE JC, KEOWN PA, MARCUSSEN N, MIHATSCH MJ, Morozumi K, MYERS BD, NAST CC, OLSEN S, RACUSEN LC, RAMOS EL, ROSEN S, SACHS DH, SALOMON

DR, SANFILIPPO F, VERANI R, VON WILLEBRAND E, YAMAGUCHI Y: International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. *Kidney Int* **44:** 411-422, 1993

SOLEZ K, RACUSEN LC: The Banff classification revisited. *Kidney Int.* **83**: 201–206, 2013.

SUTHANTHIRAN M, SCHWARTZ JE, DING R, ABECASSIS M, DADHANIA D, SAMSTEIN B, KNECHTLE SJ, FRIEDEWALD J, BECKER YT, SHARMA V, WILLIAMS NM, CHANG CS, HOANG C, MUTHUKUMAR T, AUGUST P, KESLAR KS, FAIRCHILD RL, HRICIK DE, HEEGER PS, HAN L, LIU J, RIGGS M, IKLE DN, BRIDGES ND, SHAKED A: Urinary-Cell mRNA Profile and Acute Cellular Rejection in Kidney Allografts. *N Engl J Med* **369**: 20–31, 2013.

TYCOVÁ I, HRUBÁ P, MAIXNEROVÁ D, GIRMANOVÁ E, MRÁZOVÁ P, STRAŇAVOVÁ L, ZACHOVAL R, MERTA M, SLATINSKÁ J, KOLLÁR M, HONSOVÁ E, TESAŘ V, VIKLICKÝ O: Molecular profiling in IgA nephropathy and focal and segmental glomerulosclerosis. *Physiol Res* **67**: 93–105, 2018.

VENNER JM, FAMULSKI KS, REEVE J, CHANG J, HALLORAN PF: Relationships among injury, fibrosis, and time in human kidney transplants. *JCI Insight* **1**: e85323, 2016.

VIKLICKY O, HRIBOVA P, VOLK HD, SLATINSKA J, PETRASEK J, BANDUR S, HONSOVA E, REINKE P: Molecular phenotypes of acute rejection predict kidney graft prognosis. *J Am Soc Nephrol* **21**: 173–180, 2010.